Evidence map›Paper›PMID 24386376›Full record

ArticlePloS one2013

Targeting human telomeric G-quadruplex DNA and inhibition of telomerase activity with [(dmb)2Ru(obip)Ru(dmb)2](4+).

Shuo Shi, Shane Gao, Tongcheng Cao, Jie Liu, Xing Gao, Jian Hao, Chunyan Lv, Hailiang Huang, Jun Xu, Tianming Yao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Shuo ShiDepartment of Chemistry, Tongji University, Shanghai, China.
Shane GaoEast Hospital, Tongji University School of Medicine, Shanghai, China.
Tongcheng CaoDepartment of Chemistry, Tongji University, Shanghai, China.
Jie LiuDepartment of Chemistry, Jinan University, Guangzhou, China.
Xing GaoDepartment of Chemistry, Tongji University, Shanghai, China.
Jian HaoDepartment of Chemistry, Tongji University, Shanghai, China.
Chunyan LvDepartment of Chemistry, Tongji University, Shanghai, China.
Hailiang HuangDepartment of Chemistry, Tongji University, Shanghai, China.
Jun XuEast Hospital, Tongji University School of Medicine, Shanghai, China.
Tianming YaoDepartment of Chemistry, Tongji University, Shanghai, China.
Tongji University · CNJinan University · CNShanghai East Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibition of telomerase by inducing/stabilizing G-quadruplex formation is a promising strategy to design new anticancer drugs. We synthesized and characterized a new dinuclear complex [(dmb)2Ru(obip)Ru(dmb)2](4+) (dmb = 4,4'-dimethyl-2,2'-bipyridine, obip = (2-(2-pyridyl)imidazo[4,5-f][1,10]phenanthroline) with high affinity for both antiparallel and mixed parallel / antiparallel G-quadruplex DNA. This complex can promote the formation and stabilize G-quadruplex DNA. Dialysis and TRAP experiments indicated that [(dmb)2Ru(obip)Ru(dmb)2](4+) acted as an excellent telomerase inhibitor due to its obvious selectivity for G-quadruplex DNA rather than double stranded DNA. In vitro co-culture experiments implied that [(dmb)2Ru(obip)Ru(dmb)2](4+) inhibited telomerase activity and hindered cancer cell proliferation without side effects to normal fibroblast cells. TUNEL assay indicated that inhibition of telomerase activity induced DNA cleavage further apoptosis in cancer cells. Therefore, Ru(II) complex represents an exciting opportunity for anticancer drug design by specifically targeting cancer cell G-quadruplexes DNA.

Indexed as

Antineoplastic AgentsEnzyme InhibitorsOrganometallic CompoundsRutheniumCell LineDNAHumansTelomeraseTelomereAntineoplastic AgentsDNAEnzyme InhibitorsOrganometallic CompoundsRutheniumTelomerase

Identifiers

PMID24386376
PMCPMC3874006
OpenAlexW2066486813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.